Bionano Genomics Framtida tillväxt
Future kriterier kontrolleras 2/6
Bionano Genomics förväntas öka vinsten och intäkterna med 41.4% och 21.5% per år respektive medan EPS förväntas växa med 59.4% per år.
Viktig information
41.4%
Tillväxttakt i vinsten
59.42%
Tillväxttakt för EPS
| Life Sciences vinsttillväxt | 17.3% |
| Intäkternas tillväxttakt | 21.5% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 28 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jun 08
BNGO: Clinical Genomic Wins Will Drive Future Quality Control Breakthroughs
Analysts have maintained their price target for Bionano Genomics at $4.00, citing minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook, and future P/E inputs that together support keeping the previous valuation level unchanged. What's in the News Researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine published a Modern Pathology study reporting that Bionano's optical genome mapping, or OGM, detected genomic abnormalities in 97.8% of T cell acute lymphoblastic leukemia cases, compared with 55% using conventional cytogenetic analysis, and provided additional genomic insights beyond standard methods in about 70% of cases.
Uppdatering av berättelse • May 25
BNGO: Growing Clinical Use Cases Will Support Future Upside Potential
Analysts have nudged their price target on Bionano Genomics slightly higher to $6.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E, which modestly adjust their outlook on the stock. What's in the News The company issued revenue guidance for Q2 2026, targeting US$7.5 million to US$7.8 million in revenue.Uppdatering av berättelse • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).Uppdatering av berättelse • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).Uppdatering av berättelse • Apr 05
BNGO: Future Gene Editing Quality Control Breakthroughs Will Drive Upside Potential
Analysts have cut their price target on Bionano Genomics roughly in half, to around $4.00 from about $8.00, pointing to a higher discount rate, slightly softer revenue growth expectations near 26%, a modestly better profit margin near 16%, and a higher future P/E multiple closer to 8x as key drivers of the reset. What's in the News A multicenter study in the American Journal of Hematology reported that Bionano's optical genome mapping, or OGM, was concordant with traditional methods in multiple myeloma and identified pathogenic or likely pathogenic abnormalities in a large cohort of 211 samples, including cases where standard tests such as karyotyping and FISH did not yield results (American Journal of Hematology).
Uppdatering av berättelse • Mar 22
BNGO: Gene Editing Safety Data Will Support Future Upside Potential
Analysts have adjusted their price target for Bionano Genomics slightly, reflecting updated assumptions around discount rate, profit margin, revenue growth and future P/E. Together, these factors point to a modest recalibration of their valuation outlook in dollar terms.Uppdatering av berättelse • Mar 07
BNGO: Gene Editing Safety Insights Will Support Long-Term Upside Potential
Analysts have lowered their price target on Bionano Genomics by $2.00 to $5.50, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively point to a more conservative outlook for the shares.Uppdatering av berättelse • Feb 20
BNGO: Gene Editing Study And Mapping Sensitivity Will Support Future Upside
Analysts have raised their price target for Bionano Genomics to $12.59 from $12.37, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect a recalibrated risk and earnings profile. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used optical genome mapping, or OGM, to assess genomic alterations from multiple gene editing approaches, including transposons, lentiviral transduction, and CRISPR-Cas9 locus insertion (Key Developments).Uppdatering av berättelse • Feb 06
BNGO: Gene Editing QC Study Will Support Long-Term Upside
Analysts have trimmed their price targets for Bionano Genomics, citing slightly higher assumed discount rates and modest tweaks to long term revenue growth, profit margin and future P/E assumptions that leave their fair value estimate broadly unchanged at around $8.00. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used its optical genome mapping (OGM) technology to detect genomic alterations introduced by transposons, lentiviral transduction and CRISPR-Cas9 locus insertion in human iPSC lines, supporting OGM as a potential tool for genome integrity QC in gene editing workflows (Key Developments).Analysartikel • Jan 30
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues
With a price-to-sales (or "P/S") ratio of 0.5x Bionano Genomics, Inc. ( NASDAQ:BNGO ) may be sending very bullish...Uppdatering av berättelse • Jan 23
BNGO: Clinical Study And Genome Mapping Progress Will Support Future Upside
Analysts have adjusted their price target on Bionano Genomics slightly, reflecting modest tweaks to assumptions on discount rate, profit margin, and future P/E. These changes keep their fair value estimate broadly unchanged at about $7.50 per share.Uppdatering av berättelse • Jan 09
BNGO: Leukemia Study And 2025 Revenue Outlook Will Support Long-Term Upside
Analysts have slightly adjusted their price target for Bionano Genomics, citing modest tweaks in assumptions around discount rate, revenue growth, profit margin, and future P/E as the drivers of this update. What's in the News Bionano Genomics issued earnings guidance for the fourth quarter of 2025, with revenue projected in a range of US$7.5 million to US$7.9 million.Uppdatering av berättelse • Dec 23
BNGO: Study-Driven Revenue Outlook Will Support Stronger Long-Term Upside Potential
Analysts have lowered their fair value estimate for Bionano Genomics from 11.00 dollars to 8.00 dollars. This reflects a higher perceived risk and cost of capital, despite slightly stronger expectations for revenue growth, profitability, and future valuation multiples.Uppdatering av berättelse • Dec 09
BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025
Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).Uppdatering av berättelse • Nov 25
BNGO: Clinical Study Results Will Drive Increased Demand Through 2025
Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).Analysartikel • Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders would be excited to see that the share price has had a great month...Uppdatering av berättelse • Aug 15
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.Analysartikel • Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy...
Ny berättelse • Apr 16
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Analysartikel • Apr 05
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
To the annoyance of some shareholders, Bionano Genomics, Inc. ( NASDAQ:BNGO ) shares are down a considerable 26% in the...Analysartikel • Feb 11
Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders that were waiting for something to happen have been dealt a blow...Analysartikel • Dec 17
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Analysartikel • Aug 29
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 55 | -16 | N/A | N/A | 1 |
| 12/31/2027 | 43 | -23 | N/A | N/A | 1 |
| 12/31/2026 | 32 | -29 | N/A | N/A | 2 |
| 3/31/2026 | 29 | -32 | -19 | -19 | N/A |
| 12/31/2025 | 29 | -26 | -16 | -16 | N/A |
| 9/30/2025 | 29 | -39 | -19 | -19 | N/A |
| 6/30/2025 | 27 | -74 | -26 | -26 | N/A |
| 3/31/2025 | 28 | -84 | -44 | -44 | N/A |
| 12/31/2024 | 31 | -112 | -69 | -69 | N/A |
| 9/30/2024 | 33 | -136 | -93 | -92 | N/A |
| 6/30/2024 | 37 | -204 | -106 | -105 | N/A |
| 3/31/2024 | 37 | -227 | -122 | -121 | N/A |
| 12/31/2023 | 36 | -232 | -127 | -125 | N/A |
| 9/30/2023 | 34 | -227 | -132 | -130 | N/A |
| 6/30/2023 | 32 | -147 | -136 | -133 | N/A |
| 3/31/2023 | 30 | -140 | -127 | -125 | N/A |
| 12/31/2022 | 28 | -133 | -128 | -125 | N/A |
| 9/30/2022 | 26 | -117 | -119 | -116 | N/A |
| 6/30/2022 | 23 | -106 | -109 | -106 | N/A |
| 3/31/2022 | 21 | -92 | -93 | -91 | N/A |
| 12/31/2021 | 18 | -72 | -73 | -72 | N/A |
| 9/30/2021 | 16 | -61 | -59 | -58 | N/A |
| 6/30/2021 | 13 | -51 | -49 | -49 | N/A |
| 3/31/2021 | 11 | -41 | -44 | -44 | N/A |
| 12/31/2020 | 9 | -41 | -38 | -38 | N/A |
| 9/30/2020 | 7 | -37 | -36 | -36 | N/A |
| 6/30/2020 | 8 | -33 | -32 | -32 | N/A |
| 3/31/2020 | 9 | -32 | -31 | -31 | N/A |
| 12/31/2019 | 10 | -30 | N/A | -30 | N/A |
| 9/30/2019 | 11 | -28 | N/A | -24 | N/A |
| 6/30/2019 | 11 | -27 | N/A | -23 | N/A |
| 3/31/2019 | 12 | -23 | N/A | -20 | N/A |
| 12/31/2018 | 12 | -18 | N/A | -20 | N/A |
| 9/30/2018 | 11 | -18 | N/A | -19 | N/A |
| 6/30/2018 | 11 | -18 | N/A | -18 | N/A |
| 3/31/2018 | 10 | -22 | N/A | -20 | N/A |
| 12/31/2017 | 10 | -23 | N/A | -21 | N/A |
| 12/31/2016 | 7 | -19 | N/A | -23 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: BNGO förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: BNGO förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: BNGO förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: BNGO s intäkter ( 21.5% per år) förväntas växa snabbare än US marknaden ( 11.9% per år).
Hög tillväxtintäkter: BNGO s intäkter ( 21.5% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om BNGO s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/09 08:07 |
| Aktiekurs vid dagens slut | 2026/06/09 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Bionano Genomics, Inc. bevakas av 5 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |